IL17A and myelodysplastic syndrome: Results showed that levels of PB IL-17 in patients with H-MDS (22.44 ± 5.64 pg/mL) were markedly lower than those in patients with L-MDS (30.29 ± 5.97 pg/mL, P < 0.001) and HC group (28.11 ± 4.64 pg/mL, P = 0.01) (Figure 4(a)); levels of BM IL-17 in H-MDS group (131.67 ± 49.71 pg/mL) were also significantly lower than those in patients with L-MDS (199.71 ± 61.49 pg/mL, P < 0.001) and HC group (173.59 ± 52.70 pg/mL, P = 0.015) (Figure 4(b)).